Анализ акций INDSWFTLAB.NS
IN
Нет оценки
Количественный анализ Eyestock не покрывает акции IND Swift Laboratories Ltd.
Рейтинг
Для оценки качества бизнеса компании мы собрали все финансовые данные из отчетов и представили их в виде одного числа - рейтинга компании. Значение рейтинга 100 является пороговым для определения актуальной инвестиционной идеи.
Низкий рейтинг
Капитализация млрд. $
0.022
Дивидендная доходность
—
Оборот
59.087 млрд
Сайт компании
https://www.indswiftlabs.com/Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh and currently employs 1,496 full-time employees. The company went IPO on 2002-03-15. The firm is engaged in the business of manufacturing intermediates and formulations. The Company’s products or services include Advanced Intermediates. The company is API partner for many organizations both in generic and innovative domains. The firm offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The firm offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.